Second-line chemotherapy with the association of liposomal daunorubicin, carboplatin and etoposide in children with recurrent malignant brain tumors

Second-line chemotherapy with the association of liposomal daunorubicin, carboplatin and etoposide in children with recurrent malignant brain tumors

Progressive or recurrent high-grade gliomas are characterized by a very poor prognosis, and the relevance of second-line chemotherapy is still unassessed. Although it has been reported that liposomal anthracyclines and carboplatin show some activity in these patients, their association has never bee...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of neuro-oncology 2003-01, Vol.61 (1), p.179
Hauptverfasser: Fiorillo, A, Maggi, G, Greco, N, Migliorati, R, D'Amico, A, Caro, De, Sabbatino MS, Buffardi, F
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 1
container_start_page 179
container_title Journal of neuro-oncology
container_volume 61
creator Fiorillo, A
Maggi, G
Greco, N
Migliorati, R
D'Amico, A
Caro, De
Sabbatino MS
Buffardi, F
description Progressive or recurrent high-grade gliomas are characterized by a very poor prognosis, and the relevance of second-line chemotherapy is still unassessed. Although it has been reported that liposomal anthracyclines and carboplatin show some activity in these patients, their association has never been investigated. We have treated six children with recurrent high-grade glioma after surgery, radiotherapy and chemotherapy, and one child with progressive teratoid/rhabdoid tumor with the combination of liposomal daunorubicin and carboplatin plus etoposide. Five out of seven children showed a major response and the 29 month progression-free survival was 38%. The above regimen was feasible and children showed only little and transient hematological toxicity. In our opinion, these results justify further investigation of the above combination chemotherapy for recurrent or progressive malignant brain tumors in children.
format Article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_219549459</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>578661241</sourcerecordid><originalsourceid>FETCH-proquest_journals_2195494593</originalsourceid><addsrcrecordid>eNqNjMtKxTAQhoN4wHp5h8G1hda0J3QtintduDtMkzk2hzRTJwnie_jABvQBXP23j_9MNf1odGu00eeq6fq9acdpeLtQlymduq4bjO4b9f1ClqNrg48EdqGV80KC2xd8-rxADYApsfWYPUfgIwS_ceIVAzgskaXM3vp4BxZl5i1ULgJGB5S5gt4R1MIuPjih-PsqZIvUlKHe-PeI1c2ClctlZUnXanfEkOjmT6_U7dPj68Nzuwl_FEr5cOIisU6H-34ah2kYJ_0v6AcyzFr_</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>219549459</pqid></control><display><type>article</type><title>Second-line chemotherapy with the association of liposomal daunorubicin, carboplatin and etoposide in children with recurrent malignant brain tumors</title><source>SpringerLink Journals</source><creator>Fiorillo, A ; Maggi, G ; Greco, N ; Migliorati, R ; D'Amico, A ; Caro, De ; Sabbatino MS ; Buffardi, F</creator><creatorcontrib>Fiorillo, A ; Maggi, G ; Greco, N ; Migliorati, R ; D'Amico, A ; Caro, De ; Sabbatino MS ; Buffardi, F</creatorcontrib><description>Progressive or recurrent high-grade gliomas are characterized by a very poor prognosis, and the relevance of second-line chemotherapy is still unassessed. Although it has been reported that liposomal anthracyclines and carboplatin show some activity in these patients, their association has never been investigated. We have treated six children with recurrent high-grade glioma after surgery, radiotherapy and chemotherapy, and one child with progressive teratoid/rhabdoid tumor with the combination of liposomal daunorubicin and carboplatin plus etoposide. Five out of seven children showed a major response and the 29 month progression-free survival was 38%. The above regimen was feasible and children showed only little and transient hematological toxicity. In our opinion, these results justify further investigation of the above combination chemotherapy for recurrent or progressive malignant brain tumors in children.</description><identifier>ISSN: 0167-594X</identifier><identifier>EISSN: 1573-7373</identifier><language>eng</language><publisher>New York: Springer Nature B.V</publisher><ispartof>Journal of neuro-oncology, 2003-01, Vol.61 (1), p.179</ispartof><rights>Copyright National Library of Medicine - MEDLINE Abstracts Jan 2003</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids></links><search><creatorcontrib>Fiorillo, A</creatorcontrib><creatorcontrib>Maggi, G</creatorcontrib><creatorcontrib>Greco, N</creatorcontrib><creatorcontrib>Migliorati, R</creatorcontrib><creatorcontrib>D'Amico, A</creatorcontrib><creatorcontrib>Caro, De</creatorcontrib><creatorcontrib>Sabbatino MS</creatorcontrib><creatorcontrib>Buffardi, F</creatorcontrib><title>Second-line chemotherapy with the association of liposomal daunorubicin, carboplatin and etoposide in children with recurrent malignant brain tumors</title><title>Journal of neuro-oncology</title><description>Progressive or recurrent high-grade gliomas are characterized by a very poor prognosis, and the relevance of second-line chemotherapy is still unassessed. Although it has been reported that liposomal anthracyclines and carboplatin show some activity in these patients, their association has never been investigated. We have treated six children with recurrent high-grade glioma after surgery, radiotherapy and chemotherapy, and one child with progressive teratoid/rhabdoid tumor with the combination of liposomal daunorubicin and carboplatin plus etoposide. Five out of seven children showed a major response and the 29 month progression-free survival was 38%. The above regimen was feasible and children showed only little and transient hematological toxicity. In our opinion, these results justify further investigation of the above combination chemotherapy for recurrent or progressive malignant brain tumors in children.</description><issn>0167-594X</issn><issn>1573-7373</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><recordid>eNqNjMtKxTAQhoN4wHp5h8G1hda0J3QtintduDtMkzk2hzRTJwnie_jABvQBXP23j_9MNf1odGu00eeq6fq9acdpeLtQlymduq4bjO4b9f1ClqNrg48EdqGV80KC2xd8-rxADYApsfWYPUfgIwS_ceIVAzgskaXM3vp4BxZl5i1ULgJGB5S5gt4R1MIuPjih-PsqZIvUlKHe-PeI1c2ClctlZUnXanfEkOjmT6_U7dPj68Nzuwl_FEr5cOIisU6H-34ah2kYJ_0v6AcyzFr_</recordid><startdate>20030101</startdate><enddate>20030101</enddate><creator>Fiorillo, A</creator><creator>Maggi, G</creator><creator>Greco, N</creator><creator>Migliorati, R</creator><creator>D'Amico, A</creator><creator>Caro, De</creator><creator>Sabbatino MS</creator><creator>Buffardi, F</creator><general>Springer Nature B.V</general><scope>7TK</scope><scope>K9.</scope></search><sort><creationdate>20030101</creationdate><title>Second-line chemotherapy with the association of liposomal daunorubicin, carboplatin and etoposide in children with recurrent malignant brain tumors</title><author>Fiorillo, A ; Maggi, G ; Greco, N ; Migliorati, R ; D'Amico, A ; Caro, De ; Sabbatino MS ; Buffardi, F</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_journals_2195494593</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fiorillo, A</creatorcontrib><creatorcontrib>Maggi, G</creatorcontrib><creatorcontrib>Greco, N</creatorcontrib><creatorcontrib>Migliorati, R</creatorcontrib><creatorcontrib>D'Amico, A</creatorcontrib><creatorcontrib>Caro, De</creatorcontrib><creatorcontrib>Sabbatino MS</creatorcontrib><creatorcontrib>Buffardi, F</creatorcontrib><collection>Neurosciences Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><jtitle>Journal of neuro-oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fiorillo, A</au><au>Maggi, G</au><au>Greco, N</au><au>Migliorati, R</au><au>D'Amico, A</au><au>Caro, De</au><au>Sabbatino MS</au><au>Buffardi, F</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Second-line chemotherapy with the association of liposomal daunorubicin, carboplatin and etoposide in children with recurrent malignant brain tumors</atitle><jtitle>Journal of neuro-oncology</jtitle><date>2003-01-01</date><risdate>2003</risdate><volume>61</volume><issue>1</issue><spage>179</spage><pages>179-</pages><issn>0167-594X</issn><eissn>1573-7373</eissn><abstract>Progressive or recurrent high-grade gliomas are characterized by a very poor prognosis, and the relevance of second-line chemotherapy is still unassessed. Although it has been reported that liposomal anthracyclines and carboplatin show some activity in these patients, their association has never been investigated. We have treated six children with recurrent high-grade glioma after surgery, radiotherapy and chemotherapy, and one child with progressive teratoid/rhabdoid tumor with the combination of liposomal daunorubicin and carboplatin plus etoposide. Five out of seven children showed a major response and the 29 month progression-free survival was 38%. The above regimen was feasible and children showed only little and transient hematological toxicity. In our opinion, these results justify further investigation of the above combination chemotherapy for recurrent or progressive malignant brain tumors in children.</abstract><cop>New York</cop><pub>Springer Nature B.V</pub></addata></record>
fulltext fulltext
identifier ISSN: 0167-594X
ispartof Journal of neuro-oncology, 2003-01, Vol.61 (1), p.179
issn 0167-594X
1573-7373
language eng
recordid cdi_proquest_journals_219549459
source SpringerLink Journals
title Second-line chemotherapy with the association of liposomal daunorubicin, carboplatin and etoposide in children with recurrent malignant brain tumors
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-11T11%3A05%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Second-line%20chemotherapy%20with%20the%20association%20of%20liposomal%20daunorubicin,%20carboplatin%20and%20etoposide%20in%20children%20with%20recurrent%20malignant%20brain%20tumors&rft.jtitle=Journal%20of%20neuro-oncology&rft.au=Fiorillo,%20A&rft.date=2003-01-01&rft.volume=61&rft.issue=1&rft.spage=179&rft.pages=179-&rft.issn=0167-594X&rft.eissn=1573-7373&rft_id=info:doi/&rft_dat=%3Cproquest%3E578661241%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=219549459&rft_id=info:pmid/&rfr_iscdi=true